20 Posts Not to Miss from ESMO Congress 2026: Day 1
HERIZON-GEA-01 at ESMO 2026: Updated Overall Survival With Zanidatamab-Based First-Line Treatment in HER2-Positive Gastroesophageal Adenocarcinoma
OncoDaily Grand Rounds at ESMO 2026: All You Need to Know About Sarcoma
Episode 2 of gastrochat: A Menti B, a Gut Feeling, and a Very Strange Commercial
What’s New On Radiotherapy of Lung Cancer in 2026?
Research and Advocacy Opportunity - Pancreatic Cancer Ireland Patient and Family Experience Survey
Meet the Faculty of OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition
Where to Take the Best Breaks at ESMO Congress 2026: Coffee, Sweets, and a Little Fun
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
